Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5713737 | American Journal of Otolaryngology | 2017 | 8 Pages |
Abstract
Bevacizumab is associated with both septal perforation and more widespread sinonasal toxicity. These lesions tend to produce only mild symptoms and can usually be managed conservatively. The decision to hold bevacizumab therapy should be made in conjunction with the patient and medical oncologist. Otolaryngologists should be aware of the toxicity from this increasingly common oncologic therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Otorhinolaryngology and Facial Plastic Surgery
Authors
Mathew Geltzeiler, Toby O. Steele,